Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
Am J Gastroenterol
; 2023 Oct 09.
Article
in En
| MEDLINE
| ID: mdl-37811776
ABSTRACT
INTRODUCTION:
Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD).METHODS:
We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls.RESULTS:
After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of -6.9 ± 8.3 and -8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically.DISCUSSION:
AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
Language:
En
Journal:
Am J Gastroenterol
Year:
2023
Type:
Article
Affiliation country:
United States